A Northwestern-Broad team has shown that inhibiting Aurora-A induces cancer cell differentiation in acute megakaryoblastic leukemia, thus providing a therapeutic benefit in a mouse model of the disease. The researchers hope to start clinical trials of Aurora-A inhibitors in patients with adult AMKL next summer.